Novo Nordisk’s hopes of revolutionizing obesity treatment with its CagriSema drug have been cast into doubt following disappointing trial results, including lower-than-expected weight loss percentages in late-stage trials for patients with type 2 diabetes and comorbidities. These results led to a significant drop in Novo’s stock value, as investors had high expectations for CagriSema as a potential competitor to existing GLP-1 medications. The company’s shares have plummeted around 50% from their 2024 peak, reflecting a negative sentiment among investors and analysts alike.
Full Article
Loading PerspectiveSplit analysis...
